India's First Indigenous COVID-19 Vaccine Resolves Unintentional Omission

Donald Hackett — Sun, 23 Jun 2024 16:38:28 +0000

Reviewer:

Bharat Biotech International Limited (BBIL) recently stated X that the company unintentionally omitted the Indian Council of Medical Research (ICMR) as a co-owner of the inactivated COVAXIN® vaccine patent.

On June 22, 2024, the Hyderabad-based vaccine producer Tweeted that it was taking legal action to correct this issue.

According to media reporting, ICMR was to receive a 5% royalty on net sales and product branding rights, which include 'co-inventor' status.

COVAXIN was developed from a SARS-CoV-2 coronavirus strain isolated at the National Institute of Virology, under the ICMR. The government health research agency also supported the vaccine's clinical development through assistance in conducting clinical trials.

This non-mRNA vaccine was developed using Whole-Virion Inactivated Vero Cell-derived platform technology.

During the initial stages of the recent pandemic, the World Health Organization Listed the COVAXIN vaccine as effective in November 2021.

BBIL says inactivated vaccines do not replicate and are unlikely to revert and cause pathological effects. They contain dead viruses, incapable of infecting people but still able to instruct the immune system to mount a defensive reaction against an infection.

However, a report published in Springer Nature in August 2023 found certain people were at a higher risk of adverse events after receiving COVAXIN.

As of June 2024, COVAXIN is available in about 14 countries, but not the United States.

Sub Title:

Bharat Biotech may own Indian Council of Medical Research 5% royalties on vaccine sales

References:

The Print

June 22, 2024 Tweet on X

Image:

Google News Keywords:

health, vaccines, vaccinations

Featured:

Fact checked:

Monday, June 24, 2024 - 05:45

Image Caption:

by Jens P. Raak

Consumers Want Choice of COVID Vaccines

Karen McClorey Hackett — Thu, 17 Feb 2022 22:10:50 +0000

Reviewer:

Robert Carlson, MD

More than one year after the first COVID-19 vaccine was administered in the United States, new data from a recent survey conducted online by The Harris Poll show 73% of consumers would like to see additional COVID-19 vaccines become available.

Currently, the World Health Organization has listed ten different COVID-19 vaccines based on various technologies.

But the U.S. FDA has only authorized/approved three COVID-19 vaccines.

Moreover, consumers would like to see COVID-19 vaccines developed from traditional methods, such as technologies used to produce diphtheria, mumps, chickenpox, or polio vaccines.

Other key findings from the survey include, but are limited to the following:

70% of Americans believe it’s essential for children to be vaccinated against COVID-19,
75% of vaccinated Americans agree that if a COVID-19 booster is recommended every six months, they will get it, and
41% of parents with children under age 18 who have not yet vaccinated their children for COVID-19 say they would be more likely to get their child vaccinated if there were a new vaccine that was more effective against multiple variants and emerging variants of concern.

The Harris Poll conducted this survey online within the United States on behalf of Ocugen, Inc. from February 3-7, 2022, among 2,015 adults. This online survey is not based on a probability sample and therefore no estimate of theoretical sampling error can be calculated.

The Harris Poll is one of the longest-running surveys in the U.S. tracking public opinion and social sentiment since 1963.

Dr. Shankar Musunuri, Chairman, CEO, and Co-Founder, Ocugen, Inc., stated in a press release issued on February 15, 2022, “All safe and effective options should be considered to manage the (COVID-19) pandemic.”

Ocugen has partnered with India-based Bharat Biotech and is seeking U.S. FDA and Canada’s authorization to deliver the Covaxin Whole-Virion Inactivated COVID-19 vaccine.

Having delivered more than 4 billion vaccine doses worldwide, Bharat Biotech continues to lead innovation. It has developed vaccines for influenza H1N1, Rotavirus, Japanese Encephalitis, Rabies, Chikungunya, Zika, and the world’s first tetanus-toxoid conjugated vaccine for Typhoid. Click here to learn more about Bharat Biotech.

To learn more about Pennsylvania-based Ocugen, Inc., click here.

PrecisionVaccinations publishes fact-checked, research-based antibody, antiviral, and vaccine news.

Sub Title:

Americans want COVID-19 vaccines developed from traditional technologies

References:

Ocugen/Harris Poll Finds Americans Want More COVID-19 Vaccine Options

VACCINES CANDIDATES IN CLINICAL TRIALS

Covaxin COVID-19 Vaccine

Image:

Google News Keywords:

health, vaccines, vaccinations, covid-19, WHO approved covid, covid vaccines, covaxin, novavax

Featured:

Fact checked:

Friday, February 18, 2022 - 05:45